Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glucose-regulated protein 78 (GRP78) is expressed as part of the molecular response to endoplasmic reticulum (ER) stress and mediates protein folding within the cell. GRP78 is also an important biomarker of cancer progression and the therapeutic response of patients with different cancer types. However, the role of GRP78 in the cytotoxic effect of 17-DMAG in colon cancer cells remains unclear. GRP78 expression was knocked down by small interfering RNA (siRNA). The anticancer effects of 17-DMAG were assessed by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometric cell-cycle analysis, and an Annexin V-propidium iodide (PI) apoptotic assay. We found that HT-29 cells expressed a lower level of GRP78 compared with DLD-1 cells. The MTT assay revealed that HT-29 cells were more sensitive to 17-DMAG treatment than DLD-1 cells. GRP78 knock down (GRP78KD) cells demonstrated an increased sensitivity to 17-DMAG treatment compared with the scrambled control cells. Based on the cell-cycle analysis and Annexin V-PI apoptotic assay, apoptosis dramatically increased in GRP78KD cells compared with scrambled control DLD-1 cells after these cells were treated with 17-DMAG. Finally, we observed a decrease in the level of Bcl-2 and an increase in the levels of Bad and Bax in GRP78KD cells treated with 17-DMAG. These results are consistent with an increased sensitivity to 17-DMAG after knock down of GRP78. The level of GRP78 expression may determine the therapeutic efficacy of 17-DMAG against colon cancer cells.

Original languageEnglish
Pages (from-to)4367-4376
Number of pages10
JournalTumor Biology
Volume36
Issue number6
DOIs
Publication statusPublished - Jun 11 2015

Fingerprint

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
Colonic Neoplasms
Therapeutics
HT29 Cells
Propidium
Annexin A5
Cell Cycle
glucose-regulated proteins
Endoplasmic Reticulum Stress

Keywords

  • 17-DMAG
  • Anti-proliferation
  • Colon cancer
  • GRP78
  • Hsp90

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells. / Chang, Yu Jia; Huang, Chien Yu; Hung, Chin Sheng; Liu, Hui Hsiung; Wei, Po Li.

In: Tumor Biology, Vol. 36, No. 6, 11.06.2015, p. 4367-4376.

Research output: Contribution to journalArticle

@article{e17140e53e414bf4904131aa57bfcbff,
title = "Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells",
abstract = "Glucose-regulated protein 78 (GRP78) is expressed as part of the molecular response to endoplasmic reticulum (ER) stress and mediates protein folding within the cell. GRP78 is also an important biomarker of cancer progression and the therapeutic response of patients with different cancer types. However, the role of GRP78 in the cytotoxic effect of 17-DMAG in colon cancer cells remains unclear. GRP78 expression was knocked down by small interfering RNA (siRNA). The anticancer effects of 17-DMAG were assessed by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometric cell-cycle analysis, and an Annexin V-propidium iodide (PI) apoptotic assay. We found that HT-29 cells expressed a lower level of GRP78 compared with DLD-1 cells. The MTT assay revealed that HT-29 cells were more sensitive to 17-DMAG treatment than DLD-1 cells. GRP78 knock down (GRP78KD) cells demonstrated an increased sensitivity to 17-DMAG treatment compared with the scrambled control cells. Based on the cell-cycle analysis and Annexin V-PI apoptotic assay, apoptosis dramatically increased in GRP78KD cells compared with scrambled control DLD-1 cells after these cells were treated with 17-DMAG. Finally, we observed a decrease in the level of Bcl-2 and an increase in the levels of Bad and Bax in GRP78KD cells treated with 17-DMAG. These results are consistent with an increased sensitivity to 17-DMAG after knock down of GRP78. The level of GRP78 expression may determine the therapeutic efficacy of 17-DMAG against colon cancer cells.",
keywords = "17-DMAG, Anti-proliferation, Colon cancer, GRP78, Hsp90",
author = "Chang, {Yu Jia} and Huang, {Chien Yu} and Hung, {Chin Sheng} and Liu, {Hui Hsiung} and Wei, {Po Li}",
year = "2015",
month = "6",
day = "11",
doi = "10.1007/s13277-015-3076-0",
language = "English",
volume = "36",
pages = "4367--4376",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells

AU - Chang, Yu Jia

AU - Huang, Chien Yu

AU - Hung, Chin Sheng

AU - Liu, Hui Hsiung

AU - Wei, Po Li

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Glucose-regulated protein 78 (GRP78) is expressed as part of the molecular response to endoplasmic reticulum (ER) stress and mediates protein folding within the cell. GRP78 is also an important biomarker of cancer progression and the therapeutic response of patients with different cancer types. However, the role of GRP78 in the cytotoxic effect of 17-DMAG in colon cancer cells remains unclear. GRP78 expression was knocked down by small interfering RNA (siRNA). The anticancer effects of 17-DMAG were assessed by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometric cell-cycle analysis, and an Annexin V-propidium iodide (PI) apoptotic assay. We found that HT-29 cells expressed a lower level of GRP78 compared with DLD-1 cells. The MTT assay revealed that HT-29 cells were more sensitive to 17-DMAG treatment than DLD-1 cells. GRP78 knock down (GRP78KD) cells demonstrated an increased sensitivity to 17-DMAG treatment compared with the scrambled control cells. Based on the cell-cycle analysis and Annexin V-PI apoptotic assay, apoptosis dramatically increased in GRP78KD cells compared with scrambled control DLD-1 cells after these cells were treated with 17-DMAG. Finally, we observed a decrease in the level of Bcl-2 and an increase in the levels of Bad and Bax in GRP78KD cells treated with 17-DMAG. These results are consistent with an increased sensitivity to 17-DMAG after knock down of GRP78. The level of GRP78 expression may determine the therapeutic efficacy of 17-DMAG against colon cancer cells.

AB - Glucose-regulated protein 78 (GRP78) is expressed as part of the molecular response to endoplasmic reticulum (ER) stress and mediates protein folding within the cell. GRP78 is also an important biomarker of cancer progression and the therapeutic response of patients with different cancer types. However, the role of GRP78 in the cytotoxic effect of 17-DMAG in colon cancer cells remains unclear. GRP78 expression was knocked down by small interfering RNA (siRNA). The anticancer effects of 17-DMAG were assessed by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometric cell-cycle analysis, and an Annexin V-propidium iodide (PI) apoptotic assay. We found that HT-29 cells expressed a lower level of GRP78 compared with DLD-1 cells. The MTT assay revealed that HT-29 cells were more sensitive to 17-DMAG treatment than DLD-1 cells. GRP78 knock down (GRP78KD) cells demonstrated an increased sensitivity to 17-DMAG treatment compared with the scrambled control cells. Based on the cell-cycle analysis and Annexin V-PI apoptotic assay, apoptosis dramatically increased in GRP78KD cells compared with scrambled control DLD-1 cells after these cells were treated with 17-DMAG. Finally, we observed a decrease in the level of Bcl-2 and an increase in the levels of Bad and Bax in GRP78KD cells treated with 17-DMAG. These results are consistent with an increased sensitivity to 17-DMAG after knock down of GRP78. The level of GRP78 expression may determine the therapeutic efficacy of 17-DMAG against colon cancer cells.

KW - 17-DMAG

KW - Anti-proliferation

KW - Colon cancer

KW - GRP78

KW - Hsp90

UR - http://www.scopus.com/inward/record.url?scp=84938957960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938957960&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-3076-0

DO - 10.1007/s13277-015-3076-0

M3 - Article

C2 - 25618598

AN - SCOPUS:84938957960

VL - 36

SP - 4367

EP - 4376

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 6

ER -